文献速递慢阻肺

选择性雄激素受体调节剂治疗慢阻肺肌无力:随机对照试验

Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial.
PubMed 文献 · Thorax · 2022-10-25

这项2A期随机双盲安慰剂对照试验纳入47名绝经后女性和50名男性慢阻肺患者(FEV1占预计值30%-65%,SPPB评分3-11),在家庭运动计划基础上给予GSK2881078或安慰剂13周。结果显示GSK2881078使男性腿部力量相对基线变化优于安慰剂,瘦体重增加,但患者报告结局无变化,主要安全性发现为可逆的HDL-C降低和转氨酶一过性升高。

要点

  • GSK2881078联合运动可使男性慢阻肺患者腿部力量较安慰剂提高7.0%(90%CI 0.5-13.6)。
  • 女性腿部力量变化差异无统计学意义,绝对变化8.0 kg(90%CI -2.5-18.4)。
  • 治疗相关安全性发现为可逆的HDL-C降低和转氨酶一过性升高。

核心结论

  • GSK2881078耐受性良好,短期治疗使男性慢阻肺患者以百分比表示的腿部力量增加,优于单纯体能训练。

研究设计与样本

  • 2A期随机双盲安慰剂对照试验,纳入47名绝经后女性和50名男性慢阻肺患者,1:1随机分为每日一次口服GSK2881078组(女性1.0 mg,男性2.0 mg)或安慰剂组,治疗13周并同步进行家庭运动计划。

主要发现

  • 男性治疗组与安慰剂组调整后平均变化差异为11.8 kg(90%CI -0.5至24.0),调整后平均百分比变化差异为7.0%(90%CI 0.5至13.6)。
  • 女性治疗组与安慰剂组调整后平均变化差异为8.0 kg(90%CI -2.5至18.4),调整后平均百分比变化差异为5.2%(90%CI -4.7至15.0)。
  • 瘦体重增加,但患者报告结局未见变化。

关键数值与推荐

  • 主要终点为90天时腿部力量(单次最大重复量,绝对kg和相对%变化)及多项安全性结局。
  • 次要终点包括瘦体重、躯体功能和患者报告结局。
  • 受试者FEV1占预计值30%-65%,SPPB评分3-11。

临床怎么用

  • 在慢阻肺合并肌肉无力患者中,可考虑将SARM作为运动训练的辅助手段以改善男性腿部力量。
  • 用药期间需监测HDL-C和肝转氨酶。

局限性

  • 女性腿部力量改善未达统计学意义。
  • 患者报告结局未见改善。
  • 研究为短期(13周)2A期试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Selective androgen receptor modulators (SARMs) increase muscle mass via the androgen receptor. This phase 2A trial investigated the effects of a SARM, GSK2881078, in conjunction with exercise, on leg strength in patients with chronic obstructive pulmonary disease (COPD) and impaired physical function. METHODS: 47 postmenopausal women and 50 men with COPD (forced expiratory volume in 1 s 30%-65% predicted; short physical performance battery score: 3-11) were enrolled into a randomised double-blind, placebo control trial. Patients were randomised 1:1 to once daily placebo or oral GSK2881078 (females: 1.0 mg; males: 2.0 mg) for 13 weeks with a concurrent home-exercise programme, involving strength training and physical activity. Primary endpoints were change from baseline in leg strength at 90 days (one-repetition maximum; absolute (kg) and relative (% change)) and multiple safety outcomes. Secondary endpoints included lean body mass, physical function and patient-reported outcomes. RESULTS: GSK2881078 increased leg strength in men. The difference in adjusted mean change from baseline and adjusted mean percentage change from baseline between treatment and placebo were: for women, 8.0 kg (90% CI -2.5 to 18.4) and 5.2% (90% CI -4.7 to 15.0), respectively; for men, 11.8 kg (90% CI -0.5 to 24.0) and 7.0% (90% CI 0.5 to 13.6), respectively. Lean body mass increased, but no changes in patient-reported outcomes were observed. Reversible reductions in high-density lipoprotein-cholesterol and transient elevations in hepatic transaminases were the main treatment-related safety findings. CONCLUSIONS: GSK2881078 was well tolerated and short-term treatment increased leg strength, when expressed as per cent predicted, in men with COPD more than physical training alone. TRIAL REGISTRATION NUMBER: NCT03359473.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Mohan D, Rossiter H, Watz H, et al. Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial. Thorax. 2022. PMID: 36283827. doi:10.1136/thorax-2021-218360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。